RU2011115815A - Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии - Google Patents
Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии Download PDFInfo
- Publication number
- RU2011115815A RU2011115815A RU2011115815/15A RU2011115815A RU2011115815A RU 2011115815 A RU2011115815 A RU 2011115815A RU 2011115815/15 A RU2011115815/15 A RU 2011115815/15A RU 2011115815 A RU2011115815 A RU 2011115815A RU 2011115815 A RU2011115815 A RU 2011115815A
- Authority
- RU
- Russia
- Prior art keywords
- receptor agonist
- pharmaceutical composition
- heart rate
- composition according
- administered
- Prior art date
Links
- 229940044601 receptor agonist Drugs 0.000 title claims abstract 19
- 239000000018 receptor agonist Substances 0.000 title claims abstract 19
- 230000001105 regulatory effect Effects 0.000 title claims abstract 12
- 238000000034 method Methods 0.000 title claims 17
- 238000002591 computed tomography Methods 0.000 title claims 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract 10
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract 10
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960001948 caffeine Drugs 0.000 claims abstract 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims abstract 8
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims abstract 7
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims abstract 7
- -1 levoprolol Chemical compound 0.000 claims abstract 7
- 229960004195 carvedilol Drugs 0.000 claims abstract 6
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000003087 receptor blocking agent Substances 0.000 claims abstract 6
- 229960003712 propranolol Drugs 0.000 claims abstract 5
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960003556 aminophylline Drugs 0.000 claims abstract 4
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960002237 metoprolol Drugs 0.000 claims abstract 4
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960001476 pentoxifylline Drugs 0.000 claims abstract 4
- 229960000278 theophylline Drugs 0.000 claims abstract 4
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 claims abstract 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims abstract 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims abstract 3
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 claims abstract 3
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 claims abstract 3
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 claims abstract 3
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims abstract 3
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 claims abstract 3
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 claims abstract 3
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 claims abstract 3
- 108010007859 Lisinopril Proteins 0.000 claims abstract 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims abstract 3
- HTWFXPCUFWKXOP-UHFFFAOYSA-N Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 claims abstract 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002122 acebutolol Drugs 0.000 claims abstract 3
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical group CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims abstract 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims abstract 3
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950010351 amosulalol Drugs 0.000 claims abstract 3
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950010731 arotinolol Drugs 0.000 claims abstract 3
- 229960002274 atenolol Drugs 0.000 claims abstract 3
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960004374 befunolol Drugs 0.000 claims abstract 3
- 229960004324 betaxolol Drugs 0.000 claims abstract 3
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960003588 bevantolol Drugs 0.000 claims abstract 3
- HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002781 bisoprolol Drugs 0.000 claims abstract 3
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960005400 bisoprolol fumarate Drugs 0.000 claims abstract 3
- 229960001035 bopindolol Drugs 0.000 claims abstract 3
- NMBNQRJDEPOXCP-UHFFFAOYSA-N butofilolol Chemical compound CCCC(=O)C1=CC(F)=CC=C1OCC(O)CNC(C)(C)C NMBNQRJDEPOXCP-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950009191 butofilolol Drugs 0.000 claims abstract 3
- 229960002320 celiprolol Drugs 0.000 claims abstract 3
- 229960004893 cloranolol Drugs 0.000 claims abstract 3
- XYCMOTOFHFTUIU-UHFFFAOYSA-N cloranolol Chemical compound CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl XYCMOTOFHFTUIU-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002711 epanolol Drugs 0.000 claims abstract 3
- 229960003745 esmolol Drugs 0.000 claims abstract 3
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 claims abstract 3
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 claims abstract 3
- 229950008838 indenolol Drugs 0.000 claims abstract 3
- 229960001632 labetalol Drugs 0.000 claims abstract 3
- 229950005241 landiolol Drugs 0.000 claims abstract 3
- WMDSZGFJQKSLLH-RBBKRZOGSA-N landiolol Chemical compound O1C(C)(C)OC[C@H]1COC(=O)CCC(C=C1)=CC=C1OC[C@@H](O)CNCCNC(=O)N1CCOCC1 WMDSZGFJQKSLLH-RBBKRZOGSA-N 0.000 claims abstract 3
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims abstract 3
- 229960000831 levobunolol Drugs 0.000 claims abstract 3
- 229960002394 lisinopril Drugs 0.000 claims abstract 3
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims abstract 3
- 229960004255 nadolol Drugs 0.000 claims abstract 3
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims abstract 3
- 229960000619 nebivolol Drugs 0.000 claims abstract 3
- 229950000754 nipradilol Drugs 0.000 claims abstract 3
- 229960004570 oxprenolol Drugs 0.000 claims abstract 3
- 229960002035 penbutolol Drugs 0.000 claims abstract 3
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 claims abstract 3
- 229960002508 pindolol Drugs 0.000 claims abstract 3
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960002052 salbutamol Drugs 0.000 claims abstract 3
- 229960004017 salmeterol Drugs 0.000 claims abstract 3
- 229960002370 sotalol Drugs 0.000 claims abstract 3
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960003658 talinolol Drugs 0.000 claims abstract 3
- MXFWWQICDIZSOA-UHFFFAOYSA-N talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 claims abstract 3
- 229960003352 tertatolol Drugs 0.000 claims abstract 3
- 229960004605 timolol Drugs 0.000 claims abstract 3
- 229960000604 valproic acid Drugs 0.000 claims abstract 3
- TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 claims abstract 2
- 229950009770 butaxamine Drugs 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- UAORFCGRZIGNCI-UHFFFAOYSA-N nifenalol Chemical compound CC(C)NCC(O)C1=CC=C([N+]([O-])=O)C=C1 UAORFCGRZIGNCI-UHFFFAOYSA-N 0.000 claims abstract 2
- 229950000096 nifenalol Drugs 0.000 claims abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims abstract 2
- TWVUMMQUXMYOOH-UHFFFAOYSA-N tilisolol Chemical compound C1=CC=C2C(=O)N(C)C=C(OCC(O)CNC(C)(C)C)C2=C1 TWVUMMQUXMYOOH-UHFFFAOYSA-N 0.000 claims abstract 2
- 229950008411 tilisolol Drugs 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 5
- 210000004165 myocardium Anatomy 0.000 claims 4
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 claims 3
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 2
- LFTFGCDECFPSQD-NSHDSACASA-N levomoprolol Chemical compound COC1=CC=CC=C1OC[C@@H](O)CNC(C)C LFTFGCDECFPSQD-NSHDSACASA-N 0.000 claims 2
- 229950001994 levomoprolol Drugs 0.000 claims 2
- 230000002107 myocardial effect Effects 0.000 claims 2
- 230000010412 perfusion Effects 0.000 claims 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 claims 2
- 229960000203 propafenone Drugs 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- DXPOSRCHIDYWHW-UHFFFAOYSA-N Xamoterol Chemical compound C=1C=C(O)C=CC=1OCC(O)CNCCNC(=O)N1CCOCC1 DXPOSRCHIDYWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960001222 carteolol Drugs 0.000 claims 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229950008578 medroxalol Drugs 0.000 claims 1
- MPQWSYJGFLADEW-UHFFFAOYSA-N medroxalol Chemical compound C=1C=C2OCOC2=CC=1CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1 MPQWSYJGFLADEW-UHFFFAOYSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
- 229960004928 xamoterol Drugs 0.000 claims 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Фармацевтическая композиция, содержащая средство, регулирующее частоту сердечных сокращений, по меньшей мере, 10 мкг, по меньшей мере, одного агониста A2A рецепторов и, по меньшей мере, один фармацевтически приемлемый носитель. ! 2. Фармацевтическая композиция по п.1, где средство, регулирующее частоту сердечных сокращений, представляет собой не селективный антагонист аденозина. ! 3. Фармацевтическая композиция по п.1, где средство, регулирующее частоту сердечных сокращений, выбрано из группы, состоящей из кофеина, аминофиллин кофеина, дифиллина, энпрофиллина, пентоксифиллина, теофиллина, блокатора β-адренергических рецепторов и их комбинаций. ! 4. Фармацевтическая композиция по п.3, где блокатор β-адренергических рецепторов выбран из группы, состоящей из ацебутолола, албутерола, амосулалола, аротинолола, атенолола, бефунолола, бетаксолола, бевантолола, бисопролола, бисопролола фумарата, бопиндолола, буциндолола, буфетолола, бунитролола, бутаксамина, бутофилолола, каразолола, картеолола, карведилола, целипролола, клоранолола, дивалпроекса, эпанолола, карведилола, эсмолола, инденолола, ландиолола, лабеталола, левобунолола, левомопролола, лизиноприла, медроксалола, мепиндолола, метипранолола, метопролола, надолола, небиволола, нифеналола, нипрадилола, окспренолола, пенбутолола, пиндолола, пропафенона, пропранолола, салметерола, соталола, талинолола, тертатолола, тилисолола, тимолола, верапамила, ксамотерола, ксибенолола и их комбинаций. ! 5. Фармацевтическая композиция по п.1, где агонист A2A рецепторов выбран из группы, состоящей из регаденозона, биноденозона, CVT-3033 и их комбинаций. ! 6. Фармацевтическая композиция
Claims (23)
1. Фармацевтическая композиция, содержащая средство, регулирующее частоту сердечных сокращений, по меньшей мере, 10 мкг, по меньшей мере, одного агониста A2A рецепторов и, по меньшей мере, один фармацевтически приемлемый носитель.
2. Фармацевтическая композиция по п.1, где средство, регулирующее частоту сердечных сокращений, представляет собой не селективный антагонист аденозина.
3. Фармацевтическая композиция по п.1, где средство, регулирующее частоту сердечных сокращений, выбрано из группы, состоящей из кофеина, аминофиллин кофеина, дифиллина, энпрофиллина, пентоксифиллина, теофиллина, блокатора β-адренергических рецепторов и их комбинаций.
4. Фармацевтическая композиция по п.3, где блокатор β-адренергических рецепторов выбран из группы, состоящей из ацебутолола, албутерола, амосулалола, аротинолола, атенолола, бефунолола, бетаксолола, бевантолола, бисопролола, бисопролола фумарата, бопиндолола, буциндолола, буфетолола, бунитролола, бутаксамина, бутофилолола, каразолола, картеолола, карведилола, целипролола, клоранолола, дивалпроекса, эпанолола, карведилола, эсмолола, инденолола, ландиолола, лабеталола, левобунолола, левомопролола, лизиноприла, медроксалола, мепиндолола, метипранолола, метопролола, надолола, небиволола, нифеналола, нипрадилола, окспренолола, пенбутолола, пиндолола, пропафенона, пропранолола, салметерола, соталола, талинолола, тертатолола, тилисолола, тимолола, верапамила, ксамотерола, ксибенолола и их комбинаций.
5. Фармацевтическая композиция по п.1, где агонист A2A рецепторов выбран из группы, состоящей из регаденозона, биноденозона, CVT-3033 и их комбинаций.
6. Фармацевтическая композиция по п.1, где агонист A2A рецепторов представляет собой регаденозон.
7. Фармацевтическая композиция по п.1, где агонист A2A рецепторов представляет собой регаденозон, а средство, регулирующее частоту сердечных сокращений, выбрано из группы, состоящей из кофеина, аминофиллин кофеина, дифиллина, энпрофиллина, пентоксифиллина, теофиллина, метопролола и пропранолола.
8. Способ визуализации миокарда млекопитающего с помощью мультидетекторной компьютерной томографией при вызванной сосудорасширяющим средством стрессовой перфузии миокарда, включающий введение млекопитающему терапевтически эффективного количества средства, регулирующего частоту сердечных сокращений, и, по меньшей мере, 10 мкг, по меньшей мере, одного агониста A2A рецепторов и визуализацию миокарда млекопитающего.
9. Способ визуализации миокарда млекопитающего мультидетекторной компьютерной томографией при вызванной сосудорасширяющим средством стрессовой перфузии миокарда, включающий введение млекопитающему терапевтически эффективного количества средства, регулирующего частоту сердечных сокращений, и не более чем 1000 мкг, по меньшей мере, одного агониста A2A рецепторов и визуализацию миокарда млекопитающего.
10. Способ по п.8 или 9, где средство, регулирующее частоту сердечных сокращений, вводится млекопитающему перед и одновременно, по меньшей мере, с одним агонистом A2A рецепторов.
11. Способ по п.10, где агонист A2A рецепторов вводится млекопитающему в количестве в диапазоне от приблизительно 10 до приблизительно 600 мкг.
12. Способ по п.8 или 9, где агонист A2A рецепторов вводится менее чем приблизительно за 10 секунд.
13. Способ по п.8 или 9, где агонист A2A рецепторов вводится в количестве более чем приблизительно 10 мкг.
14. Способ по п.8 или 9, где агонист A2A рецепторов вводится в количестве более чем приблизительно 100 мкг.
15. Способ по п.8 или 9, где агонист A2A рецепторов вводится в количестве не более чем 600 мкг.
16. Способ по п.15, где агонист A2A рецепторов вводится в количестве не более чем 500 мкг.
17. Способ по п.8 или 9, где агонист A2A рецепторов вводится в количестве в диапазоне от приблизительно 100 мкг до приблизительно 500 мкг.
18. Способ по п.8 или 9, где агонист A2A рецепторов выбран из группы, состоящей из CVT-3033, регаденозона и их комбинаций.
19. Способ по п.8 или 9, где средство, регулирующее частоту сердечных сокращений, выбрано из группы, состоящей из кофеина, аминофиллин кофеина, дифиллина, энпрофиллина, пентоксифиллина, теофиллина, блокаторов β-адренергических рецепторов и их комбинаций.
20. Способ по п.19, где блокатор β-адренергических рецепторов выбран из группы, состоящей из ацебутолола, албутерола, амосулалола, аротинолола, атенолола, бефунолола, бетаксолола, бевантолола, бисопролола, бисопролола фумарата, бопиндолола, буциндолола, буфетолола, бунитролола, бутаксамина, бутофилолола, каразолола, картеолола, карведилола, целипролола, клоранолола, дивалпроекса, эпанолола, карведилола, эсмолола, инденолола, ландиолола, лабеталола, левобунолола, левомопролола, лизиноприла, медроксалола, мепиндолола, метипранолола, метопролола, надолола, небиволола, нифеналола, нипрадилола, окспренолола, пенбутолола, пиндолола, пропафенона, пропранолола, салметерола, соталола, талинолола, тертатолола, тилисолола, тимолола, верапамила, ксамотерола, ксибенолола и их комбинаций.
21. Способ по п.20, где блокатор β-адренергических рецепторов выбран из метопролола или пропранолола.
22. Способ по любому из п.п.8 или 9, где млекопитающее представляет собой человека.
23. Способ по любому из п.п.8 или 9, где агонист A2A рецепторов вводится в одном внутривенном болюсе.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10104308P | 2008-09-29 | 2008-09-29 | |
| US61/101,043 | 2008-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011115815A true RU2011115815A (ru) | 2012-11-10 |
Family
ID=41381642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011115815/15A RU2011115815A (ru) | 2008-09-29 | 2009-09-29 | Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100086483A1 (ru) |
| EP (1) | EP2344145A1 (ru) |
| JP (1) | JP2012504147A (ru) |
| KR (1) | KR20110063556A (ru) |
| CN (1) | CN102164591A (ru) |
| AU (1) | AU2009296235A1 (ru) |
| BR (1) | BRPI0918962A2 (ru) |
| CA (1) | CA2737077A1 (ru) |
| MX (1) | MX2011003168A (ru) |
| RU (1) | RU2011115815A (ru) |
| WO (1) | WO2010037122A1 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| WO2001062979A2 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Dentification of partial agonists of the a2a adenosine receptor |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
| JP2005538190A (ja) * | 2002-07-29 | 2005-12-15 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋潅流イメージング |
| RU2007114908A (ru) * | 2004-10-20 | 2008-10-27 | Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС | Применение агонистов аденозиновых рецепторов a2a |
| CA2640089C (en) | 2006-02-03 | 2013-07-23 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| JP2010502649A (ja) * | 2006-09-01 | 2010-01-28 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋層画像化法中の患者の耐性を増加させるための方法および組成物 |
| EP2066232A1 (en) * | 2006-09-29 | 2009-06-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
| US9791353B2 (en) * | 2008-08-29 | 2017-10-17 | Research International, Inc. | Concentrator |
| US9474500B2 (en) | 2009-02-05 | 2016-10-25 | The Research Foundation Of State University Of New York | Method and system for transfer of cardiac medical image data files |
| GB201100137D0 (en) | 2011-01-06 | 2011-02-23 | Davies Helen C S | Apparatus and method of assessing a narrowing in a fluid tube |
| US20140170069A1 (en) * | 2011-05-05 | 2014-06-19 | Cedars-Sinai Medical Center | Assessment of coronary heart disease with carbon dioxide |
| US11129911B2 (en) | 2011-05-05 | 2021-09-28 | Cedars-Sinai Medical Center | Assessment of coronary heart disease with carbon dioxide |
| US11439309B2 (en) | 2011-05-05 | 2022-09-13 | Cedars-Sinai Medical Center | Assessment of coronary heart disease with carbon dioxide |
| US9339348B2 (en) | 2011-08-20 | 2016-05-17 | Imperial Colege of Science, Technology and Medicine | Devices, systems, and methods for assessing a vessel |
| EP2744400B1 (en) | 2011-08-20 | 2017-05-24 | Volcano Corporation | Devices, systems, and methods for visually depicting a vessel and evaluating treatment options |
| EP2838530B1 (en) | 2012-04-20 | 2017-04-05 | UCB Biopharma SPRL | Methods for treating parkinson's disease |
| US20150290236A1 (en) * | 2012-11-30 | 2015-10-15 | Leiutis Pharmaceuticals Pvt. Ltd. | Pharmaceutical compositions of regadenoson |
| WO2015021078A1 (en) | 2013-08-05 | 2015-02-12 | Cedars-Sinai Medical Center | Methods for reducing ischemia-reperfusion injury |
| JOP20190219A1 (ar) * | 2017-05-09 | 2019-09-22 | Cardix Therapeutics LLC | تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
| US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
| SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
| US4328525A (en) * | 1980-06-27 | 1982-05-04 | International Business Machines Corporation | Pulsed sine wave oscillating circuit arrangement |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
| JPS6299395A (ja) * | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | ２−アルキニルアデノシンおよび抗高血圧剤 |
| DK163128C (da) * | 1986-08-12 | 1992-06-15 | Hoffmann La Roche | Pyrimidinnucleosider, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater indeholdende pyrimidinnucleosiderne og anvendelse af pyrimidinnucleosiderne |
| US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
| WO1990005526A1 (fr) * | 1988-11-15 | 1990-05-31 | Yamasa Shoyu Kabushiki Kaisha | Agent de traitement et de prophylaxie des troubles ischemiques du c×ur ou du cerveau |
| DE69022176T2 (de) * | 1989-06-20 | 1996-02-15 | Toa Eiyo Ltd., Tokio/Tokyo | Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat. |
| US5032252A (en) * | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
| DE4013842A1 (de) * | 1990-04-30 | 1991-10-31 | Ant Nachrichtentech | Verfahren zur aufbereitung von bilddaten fuer uebertragungszwecke sowie anwendung |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| JP2740362B2 (ja) * | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | 安定な固体状２‐オクチニルアデノシンおよびその製造法 |
| US5516894A (en) * | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| EP0601322A3 (en) * | 1992-10-27 | 1994-10-12 | Nippon Zoki Pharmaceutical Co | Adenosine deaminase inhibitor. |
| CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
| WO1995023148A1 (en) * | 1994-02-23 | 1995-08-31 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
| US5704491A (en) * | 1995-07-21 | 1998-01-06 | Cummins-Allison Corp. | Method and apparatus for discriminating and counting documents |
| US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
| US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US6448235B1 (en) * | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
| US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
| US5854081A (en) * | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
| US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
| US5776960A (en) * | 1996-10-16 | 1998-07-07 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same |
| US5770716A (en) * | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
| US6026317A (en) * | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6368294B2 (en) * | 1999-02-24 | 2002-04-09 | Gregory Quinn | Massaging surface |
| US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| US6368573B1 (en) * | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
| US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
| US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| WO2001062979A2 (en) * | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Dentification of partial agonists of the a2a adenosine receptor |
| US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
| US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
| US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
| CN1268610C (zh) * | 2001-05-14 | 2006-08-09 | 诺瓦提斯公司 | 磺酰胺衍生物 |
| PL370207A1 (en) * | 2001-11-09 | 2005-05-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| AU2002366811B2 (en) * | 2001-12-20 | 2009-01-15 | Osi Pharmaceuticals, Inc. | Pyrimidine A2B selective antagonist compounds, their synthesis and use |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| CA2482928A1 (en) * | 2002-04-18 | 2003-10-30 | Cv Therapeutics, Inc. | Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside |
| JP2005538190A (ja) * | 2002-07-29 | 2005-12-15 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋潅流イメージング |
| US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
| BRPI0412285A (pt) * | 2003-07-02 | 2006-09-19 | Hoffmann La Roche | os compostos de quinazolinona substituìda por arilamina |
| GB0317815D0 (en) * | 2003-07-30 | 2003-09-03 | Amersham Health As | Imaging agents |
| US7025883B1 (en) * | 2003-09-30 | 2006-04-11 | Ok Technologies, Llc | Autotrofic sulfur denitration chamber and calcium reactor |
| AU2004316372B2 (en) * | 2004-01-27 | 2011-05-12 | Gilead Sciences, Inc. | Myocardial perfusion imaging using adenosine receptor agonists |
| US20060159627A1 (en) * | 2004-10-15 | 2006-07-20 | Dewan Zeng | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
| RU2007114908A (ru) * | 2004-10-20 | 2008-10-27 | Си Ви ТЕРАПЬЮСи Ви ТЕРАПЬЮТИКСИКС | Применение агонистов аденозиновых рецепторов a2a |
| WO2006076698A1 (en) * | 2005-01-12 | 2006-07-20 | King Pharmaceuticals Reserch & Development, Inc. | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm |
| CA2640089C (en) * | 2006-02-03 | 2013-07-23 | Cv Therapeutics, Inc. | Process for preparing an a2a-adenosine receptor agonist and its polymorphs |
| EP2068850A1 (en) * | 2006-06-22 | 2009-06-17 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| JP2010502649A (ja) * | 2006-09-01 | 2010-01-28 | シーブイ・セラピューティクス・インコーポレイテッド | 心筋層画像化法中の患者の耐性を増加させるための方法および組成物 |
| EP2066232A1 (en) * | 2006-09-29 | 2009-06-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
| US20080267861A1 (en) * | 2007-01-03 | 2008-10-30 | Cv Therapeutics, Inc. | Myocardial Perfusion Imaging |
| US20100272711A1 (en) * | 2007-12-12 | 2010-10-28 | Thomas Jefferson University | Compositions and methods for the treatment and prevention of cardiovascular diseases |
-
2009
- 2009-09-29 RU RU2011115815/15A patent/RU2011115815A/ru unknown
- 2009-09-29 US US12/569,643 patent/US20100086483A1/en not_active Abandoned
- 2009-09-29 MX MX2011003168A patent/MX2011003168A/es unknown
- 2009-09-29 CN CN200980138322XA patent/CN102164591A/zh active Pending
- 2009-09-29 JP JP2011529367A patent/JP2012504147A/ja not_active Withdrawn
- 2009-09-29 AU AU2009296235A patent/AU2009296235A1/en not_active Abandoned
- 2009-09-29 EP EP09741075A patent/EP2344145A1/en not_active Withdrawn
- 2009-09-29 CA CA2737077A patent/CA2737077A1/en not_active Abandoned
- 2009-09-29 WO PCT/US2009/058850 patent/WO2010037122A1/en not_active Ceased
- 2009-09-29 BR BRPI0918962A patent/BRPI0918962A2/pt not_active Application Discontinuation
- 2009-09-29 KR KR1020117009103A patent/KR20110063556A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2344145A1 (en) | 2011-07-20 |
| AU2009296235A1 (en) | 2010-04-01 |
| WO2010037122A1 (en) | 2010-04-01 |
| JP2012504147A (ja) | 2012-02-16 |
| CN102164591A (zh) | 2011-08-24 |
| CA2737077A1 (en) | 2010-04-01 |
| KR20110063556A (ko) | 2011-06-10 |
| US20100086483A1 (en) | 2010-04-08 |
| BRPI0918962A2 (pt) | 2015-12-01 |
| MX2011003168A (es) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011115815A (ru) | Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии | |
| De Miranda et al. | Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson’s disease | |
| RU2561729C2 (ru) | Аналоги tofa, применимые при лечении дерматологических расстройств или состояний | |
| KR101538006B1 (ko) | 체지방 및 지방세포를 감소시키는 방법 및 조성물 | |
| KR100564466B1 (ko) | Ｆｓａｄ에 대한 ｎｅｐ 억제제로서의ｎ-펜프로필사이클로펜틸-치환된 글루타르아미드 유도체 | |
| ES2282923T3 (es) | (s)-2-n-propilamino-5-hidroxi-tetralina como agente terapeutico agonista de d3. | |
| EP2083920B1 (en) | N-aryl-hydroxyalkylidene-carboxamide compounds and their use | |
| WO2006113485A2 (en) | Aminergic pharmaceutical compositions and methods | |
| JP2012529484A (ja) | 高血圧症の防止及び治療のための組成物並びに組成物の調製方法 | |
| US9464066B2 (en) | Deuterated compounds useful for treating neurodegenerative diseases | |
| RU2624446C2 (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| WO2023165094A1 (zh) | 一种羟戊苯甲酸双酯化合物及其制备方法和应用 | |
| KR20110125642A (ko) | 당뇨 및 비만을 치료하기 위한 프테로신 화합물의 용도 | |
| KR20230096985A (ko) | 면역조절제로서의 비페닐 화합물, 이의 제조방법 및 이의 적용 | |
| TW200800148A (en) | Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient | |
| ES2887338T3 (es) | Uso de un compuesto de carbamato para prevenir o tratar la neuralgia del trigémino | |
| CA2259316A1 (en) | Smooth muscle spasmolytic agents, compositions and methods of use thereof | |
| KR100459484B1 (ko) | 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물 | |
| KR20210047887A (ko) | 중첩발작의 예방, 경감 또는 치료에 대한 카바메이트 화합물의 용도 | |
| CN115745890A (zh) | 一种酯键化合物及其制备方法和应用、镇痛药物 | |
| US8518995B2 (en) | Methods and compositions for the treatment of irritable bowel syndrome | |
| RU2012112943A (ru) | Соединения для лечения расстройства или заболевания, связанного с активностью нейрокининового 2 рецептора | |
| Upadhyaya et al. | Role of an indigenous drug Geriforte on blood levels of biogenic amines and its significance in the treatment of anxiety neurosis | |
| CN113015524A (zh) | 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途 | |
| JP2003521479A5 (ru) |